ANGPTL3 and coronary artery disorder: Furthermore, WES of more than 180,000 individuals with ANGPTL3 LOF variants showed that heterozygous carriers of ANGPTL3 LOF mutations had approximately 34% lower odds of CAD than noncarriers,139 suggesting an association between CAD and plasma levels of ANGPTL3.